Compare DraftKings Inc (DKNG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Novo Nordisk A/S — how do they compare? DraftKings Inc trades at $25.33 (market cap $12.58B), while Novo Nordisk A/S trades at $45.79 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 16.5× DraftKings Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals.
| DKNG | NVO | |
|---|---|---|
Market Cap | $12.58B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $63.98 |
52-Week Low | $20.72 | $35.29 |
Enterprise Value | $13.51B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $24.27, up 1.0% today, showing mixed technical signals with a bullish overall trend but bearish moving averages. Fundamentally, the company achieved its first annual net profit in 2025 ($4M) after years of losses, with revenue growing to $6.05B. However, recent quarterly earnings have missed expectations, and valuation ratios remain elevated with a P/E of 246.33. Analyst sentiment remains positive with 73% buy ratings and a $34 consensus price target, representing 40% upside potential.
The outlook for DKNG hinges on successful execution in prediction markets and sportsbook growth, particularly with the upcoming NFL season. Key risks include intense competition from prediction market platforms, regulatory challenges, and the company's ability to maintain profitability after recently turning profitable. While technical indicators show near-term resistance at $25, the substantial analyst upside and improving cash flow trends suggest potential for long-term growth if execution improves.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
